To compare the differences between CYP2D6×10 and CYP2D6×5 gene polymorphisms in patients with non-small cell lung cancer (NSCLC) and the correlation between liver injury, skin rash and diarrhea adverse reactions after targeted therapy (geffitinib, erlotinib and crizotinib), and to explore the correlation between common adverse reactions after targeted drug therapy and CYP2D6 gene polymorphism.

NSCLC patients treated with targeted therapy (gifitinib, Erlotinib, crezoltini) from January 2016 to December 2019 were selected from the Affiliated Tumor Hospital of Xinjiang Medical University. The polymorphism of CYP2D6×10 and CYP2D6×5 genotypes and allelic frequencies were detected by using the restricted segment length polymorphism polymerase Chain reaction-restriction fragment Length polymorphism (PCR-RFLP). Genotype distribution differences and allelic differences in patients with liver injury, diarrhea, and rash were compared with those without.

There were statistically significant differences in CYP2D6×10 gene polymorphism and allele frequency between the groups with and without liver damage (P<0.05), and there was no correlation between CYP2D6×10 gene polymorphism and allele frequency difference between the skin rash group and the diarrhea group. The only factor associated with diarrhea was a history of chemotherapy (P=0.002), and the factor associated with rash was staging (P=0.000).

CYP2D6 gene polymorphism may be one of the effective indicators for the prediction of drug-induced liver injury in TARGETED NSCLC therapy, which can guide the clinical medication of NSCLC patients.